NCT07407283 2026-04-21
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
23 trialsNCT04224493 2026-04-20
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT05228158 2026-01-02
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Eisai Inc.
Active not recruiting
NCT02875548 2025-11-04
TRuST
Ipsen
Phase 1/2 Completed
NCT05372354 2025-09-05
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT02601950 2025-06-22
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
Phase 2 Completed
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT05713110 2025-01-22
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Hutchmed
Phase 2 Completed
NCT02601937 2024-10-03
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Ipsen
Phase 1 Completed
NCT04225429 2024-10-01
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Ipsen
No longer available
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT03010982 2024-03-22
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Ipsen
Phase 1 Completed
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed
NCT03009344 2022-11-10
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Inc.
Phase 1 Completed
NCT02860286 2021-04-09
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
Phase 2 Completed
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed